A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Capecitabine (Primary) ; Sunitinib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 18 Jun 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 18 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.